期刊
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
卷 5, 期 2, 页码 176-188出版社
SPRINGER
DOI: 10.1007/s11481-009-9181-3
关键词
experimental autoimmune encephalomyelitis; functional avidity; tolerance; altered peptide ligands; MHC variant peptides; SHP-1
资金
- NIH [R01 NS062358]
- National Multiple Sclerosis Society [RG 4047]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS071518, R01NS062358] Funding Source: NIH RePORTER
The development of antigen-specific therapies for the selective tolerization of autoreactive T cells remains the Holy Grail for the treatment of T-cell-mediated autoimmune diseases such as multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). This quest remains elusive, however, as the numerous antigen-specific strategies targeting myelin-specific T cells over the years have failed to result in clinical success. In this review, we revisit the antigen-based therapies used in the treatment of myelin-specific CD4+ T cells in the context of the functional avidity and the strength of signal of the encephalitogenic CD4+ T cell repertoire. In light of differences in activation thresholds, we propose that autoreactive T cells are not all equal, and therefore tolerance induction strategies must incorporate ligand strength in order to be successful in treating EAE and ultimately the human disease MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据